H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis

Exclusion criteria

• . Pregnant or lactating women, men or women who do not wish to use effective contraception;
• . Patients who have received previous treatment with lysoviruses (e.g., T-VEC), interventional therapy, or TACE;
• . Those who are being treated with antiviral drugs;
• . having received any other experimental drug, antimicrobial drug, or participated in another interventional clinical trial within 4 weeks prior to enrollment
• . Those with a known allergy to the study drug or its active ingredient, or a history of allergy to similar biological agents
• . Evidence of Child-Pugh C hepatic function or hepatocellular dysregulation, including those with refractory ascites, ruptured esophageal or gastric variceal bleeding, and hepatic encephalopathy
• . presence of a history of immunodeficiency or autoimmune disease or long-term systemic steroid therapy or any form of immunosuppressive therapy within 7 days prior to enrollment
• . With any unstable systemic disease, including but not limited to: severe infection, hypertensive patients, uncontrolled diabetes mellitus, unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia, abnormal mental status or active cerebral hemorrhage, myocardial infarction, congestive heart failure, severe arrhythmias requiring drug therapy, renal or metabolic disease, severe hepatic dysfunction (including severe jaundice, hepatic encephalopathy, refractory ascites or hepatorenal syndrome), multiple organ failure with renal dysfunction;